Frecuencias de las perdidas de heterocigocidad en la regi¨®n que codifica para HLA en biopsias de pacientes con c¨¢ncer de cuello uterino / Frequency of Heterozygosity Loss in the Region to be Encoded by HLA in Biopsies of Patients with Cervical Cancer
Rev. colomb. cancerol
;
13(4): 191-204, dic. 2009. tab, graf
Article
in Spanish
| LILACS
| ID: lil-662018
RESUMEN
Objetivo: Determinar las frecuencias de p¨¦rdidas de heterocigocidad de LOH en las regiones 6p21.3 y 15q21 que codifican para HLA y ¦Â2 microglobulina, para establecer su correlaci¨®n con el estadio tumoral, teniendo en cuenta que las LOH en HLA I ocurren como un evento gen¨¦tico temprano del c¨¢ncer y pueden contribuir a su desarrollo. M¨¦todos: Se tomaron muestras de sangre perif¨¦rica (SP) y biopsias de cuello uterino de pacientes con NICIII y CCU. Se amplificaron 11 microsat¨¦lites relacionados con el sistema HLA en pares normal-tumor a partir de ADN purificado de c¨¦lulas de SP y c¨¦lulas tumorales microdisectadas. Las LOH fueron determinadas por electroforesis capilar y analizadas mediante los programas GeneScan y Genotyper. Resultado: Todas las muestras amplificaron m¨¢s de 7 microsat¨¦lites (promedio 9,5). El porcentaje de heterocigocidad para los marcadores de microsat¨¦lites utilizados en las muestras de cuello uterino vari¨® entre 51,8% y 95%, y la LOH, entre 17,4% y 50,0%. Las frecuencias observadas para LOH en los diferentes estadios tumorales fueron: 42,9% en el grupo de NIC-III; 57% en CCU en estadio I; 63,6% en CCU en estadio II y 92,85% en pacientes con estadios m¨¢s avanzados (III-IV). Conclusi¨®n: Se observ¨® una mayor frecuencia de LOH en los grupos de pacientes con estadios avanzados de CCU, al comparar con pacientes con NIC-III.
ABSTRACT
Objective: To determine the frequency of LOH heterozygosity in the regions 6p21.3 and 15q21 which encode for HLA and ¦Â2microglobulina in order to establish their correlation with tumoral stage, taking into account that LOH and HLA I occur as an early genetic event in cancer and can contribute to its development. Methods: Peripheral blood (PB) samples and cervical biopsies were taken from patients with CIN III and invasive cancer. Amplification was made of eleven microsatellites related to the HLA system, in normal-tumor pairs, based on purified DNA PB cells and micro-dissected tumor cells. LOH were determined through capillary electrophoresis and analyzed with GeneScan and Genotyper programs. Results: All samples amplified at more than 7 microsatellites (average 9.5). The percentage of heterozygosity for microsatellite markers used in the cervical samples varied between 51.8% and 95%; the LOH, between 17.4% and 50.0%. The frequencies observed for LOH in the different tumoral stages were: 42.9% in the CIN III group; 57% in invasive cancer Stage I; 63.6% in Stage II, and 92.85% in patients in the most advanced stages (III-IV). Conclusion: Greater frequency of LOH was observed in groups of patients with advanced stages of invasive cancer in comparison with patients with CIN III.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Uterine Cervical Neoplasms
/
Microsatellite Repeats
/
Microsatellite Instability
/
Neoplasms
Limits:
Female
/
Humans
Country/Region as subject:
South America
/
Colombia
Language:
Spanish
Journal:
Rev. colomb. cancerol
Journal subject:
Neoplasias
/
Oncologia
Year:
2009
Type:
Article
Affiliation country:
Colombia
Institution/Affiliation country:
Instituto Nacional de Cancerolog¨ªa/CO
/
Universidad Nacional de Colombia/CO
Similar
MEDLINE
...
LILACS
LIS